Details of the Drug Pharmacogenomic Perturbation Atlas

Vecuronium Drug Info

Norcuron (TN); (2A,3A,5A,16A,17A)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate

Therapeutic Class

Analgesics

Cross-matching ID

PubChem CID

39765

ChEBI ID

CHEMBL1201219

CAS Number

CAS 86029-43-8

TTD Drug ID

D0Z8HG

VARIDT Drug ID

DR00716

General Information of Drug (ID: DMP0UK2)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Cell cycle	2.32	0.00e+0	110/124 (88.71%)	PCNA;CCNA2;CCND2;...
Ribosome biogenesis in eukaryotes	2.09	0.00e+0	52/108 (48.15%)	POP4;NOP56;NXT2;...
DNA replication	2.04	2.37e-3	34/36 (94.44%)	PCNA;POLE2;FEN1;...
mRNA surveillance pathway	1.95	5.34e-3	71/98 (72.45%)	NXT2;PNN;GSPT2;...
Spliceosome	1.89	9.97e-3	101/150 (67.33%)	LSM5;PUF60;SNRPD1;...
Fanconi anemia pathway	1.82	1.54e-2	36/54 (66.67%)	HES1;BRIP1;REV1;...
Base excision repair	1.79	1.42e-2	29/33 (87.88%)	PCNA;POLE2;FEN1;...
Mismatch repair	1.68	4.45e-2	22/23 (95.65%)	PCNA;RFC3;MSH6;...
Alanine, aspartate and glutamate metabolism	-1.69	2.08e-2	27/37 (72.97%)	GOT2;ASNS;GLUD1;...
Mitophagy	-1.71	1.64e-2	56/68 (82.35%)	MAPK8;RELA;OPTN;...
Various types of N-glycan biosynthesis	-1.72	1.61e-2	26/39 (66.67%)	MGAT4C;MGAT4A;MAN1A1;...
Tyrosine metabolism	-1.73	1.62e-2	30/36 (83.33%)	DCT;HGD;DDC;...
PPAR signaling pathway	-1.75	1.34e-2	66/74 (89.19%)	PLIN2;PPARD;ACOX2;...
Vitamin digestion and absorption	-1.76	1.05e-2	17/24 (70.83%)	LMBRD1;ABCC1;TCN2;...
Thyroid hormone synthesis	-1.78	1.09e-2	66/75 (88%)	ALB;ATP1A3;PAX8;...
Malaria	-1.79	9.23e-3	44/50 (88%)	MET;IL6;MYD88;...
Riboflavin metabolism	-1.84	5.11e-3	7/8 (87.5%)	ACP2;RFK;ACP1;...
Synaptic vesicle cycle	-1.84	5.35e-3	63/78 (80.77%)	AP2A2;STX2;SLC6A2;...
Steroid hormone biosynthesis	-1.84	5.62e-3	43/61 (70.49%)	CYP11B1;HSD3B1;CYP19A1;...
Fatty acid degradation	-1.85	5.92e-3	40/43 (93.02%)	ACSL6;ADH6;ACSL4;...
Collecting duct acid secretion	-1.85	6.24e-3	22/27 (81.48%)	ATP6V0D1;ATP6V0A1;ATP6V1F;...
Steroid biosynthesis	-1.87	5.14e-3	19/20 (95%)	NSDHL;FDFT1;EBP;...
Arachidonic acid metabolism	-1.88	3.90e-3	48/61 (78.69%)	PTGES2;CYP4F2;ALOX15B;...
Phenylalanine metabolism	-1.88	4.16e-3	14/17 (82.35%)	DDC;HPD;PAH;...
Synthesis and degradation of ketone bodies	-1.89	4.46e-3	9/10 (90%)	HMGCS1;ACAT2;ACAT1
Terpenoid backbone biosynthesis	-1.92	3.84e-3	18/22 (81.82%)	PMVK;PCYOX1;DHDDS;...
Other glycan degradation	-1.94	4.16e-3	13/18 (72.22%)	MAN2B1;MAN2B2;NEU1;...
Arginine biosynthesis	-1.95	4.54e-3	17/22 (77.27%)	GLUD2;GOT2;OTC;...
Phagosome	-1.95	5.00e-3	118/152 (77.63%)	HLA-G;MSR1;RAB5B;...
Epithelial cell signaling in Helicobacter pylori infect...	-1.96	4.16e-3	62/70 (88.57%)	CXCL2;JAM3;ATP6V0D1;...
Rheumatoid arthritis	-1.96	4.68e-3	78/93 (83.87%)	TCIRG1;IL6;CXCL6;...
Vibrio cholerae infection	-1.98	3.57e-3	44/50 (88%)	SEC61A1;PRKACB;GNAS;...
Ferroptosis	-2.00	4.16e-3	36/41 (87.8%)	ACSL6;FTL;LPCAT3;...
Oxidative phosphorylation	-2.01	2.50e-3	93/133 (69.92%)	NDUFS2;ATP6V0A2;ATP6V0A4;...
Mineral absorption	-2.01	3.12e-3	48/60 (80%)	ATP1B3;FTH1;TF;...
Lysosome	-2.08	4.16e-3	115/128 (89.84%)	TCIRG1;AP1G2;IGF2R;...
Retinol metabolism	-2.11	0.00e+0	41/68 (60.29%)	UGT2A3;ADH6;DGAT1;...
Complement and coagulation cascades	-2.46	0.00e+0	76/85 (89.41%)	KNG1;PLAU;C9;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
1HAEo-	CVCL_0128	Homo sapiens	10uM	24H

NL20	CVCL_0461	Homo sapiens	10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	6.66uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Normal (Fibroblast)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
HFL1	CVCL_4295	Homo sapiens	10uM	24H

IMR-90	CVCL_0347	Homo sapiens	10uM	24H

WI-38	CVCL_0579	Homo sapiens	10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H